• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gossamer Bio Inc. (Amendment)

    2/13/24 5:06:16 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOSS alert in real time by email
    SC 13G/A 1 tv01037-gossamerbioinc.htm SCHEDULE 13G/A gossamerbioinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  Gossamer Bio Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  38341P102

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  38341P102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    11,567,024

    8.  SHARED DISPOSITIVE POWER

    68,610

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    11,635,634

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.16%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Gossamer Bio Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3013 Science Park Road, Suite 200
    San Diego, CA 92121

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    38341P102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $GOSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOSS

    DatePrice TargetRatingAnalyst
    6/25/2024$9.00Outperform
    Oppenheimer
    4/5/2024$4.00Outperform
    Wedbush
    7/27/2023$8.00 → $1.25Buy → Neutral
    UBS
    3/7/2023Outperform → Mkt Perform
    Raymond James
    3/1/2023Neutral
    Guggenheim
    12/7/2022Neutral → Underweight
    JP Morgan
    12/7/2022$3.00Outperform → Neutral
    SMBC Nikko
    12/7/2022$18.00 → $2.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $GOSS
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

      Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

      6/21/24 3:17:31 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Gossamer Bio with a new price target

      Oppenheimer initiated coverage of Gossamer Bio with a rating of Outperform and set a new price target of $9.00

      6/25/24 7:48:05 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on Gossamer Bio with a new price target

      Wedbush resumed coverage of Gossamer Bio with a rating of Outperform and set a new price target of $4.00

      4/5/24 7:26:48 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio downgraded by UBS with a new price target

      UBS downgraded Gossamer Bio from Buy to Neutral and set a new price target of $1.25 from $8.00 previously

      7/27/23 9:01:18 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 4:40:26 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 9:55:14 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      8/2/24 6:30:57 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Regulatory Affairs Peterson Caryn

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:09:17 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Tech Ops and Admin Christian Waage

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:08:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Smith Robert Paul Jr

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:06:46 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Hasnain Faheem bought $250,282 worth of shares (372,000 units at $0.67) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/24/24 5:52:18 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO/CFO Giraudo Bryan bought $59,110 worth of shares (100,000 units at $0.59) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/20/24 8:21:38 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Smith Robert Paul Jr bought $15,050 worth of shares (25,000 units at $0.60) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/20/24 8:20:20 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    SEC Filings

    See more
    • Gossamer Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Gossamer Bio, Inc. (0001728117) (Filer)

      5/15/25 4:02:16 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Gossamer Bio Inc.

      10-Q - Gossamer Bio, Inc. (0001728117) (Filer)

      5/15/25 4:01:31 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Gossamer Bio Inc.

      DEFA14A - Gossamer Bio, Inc. (0001728117) (Filer)

      4/29/25 4:01:51 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

      5/20/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

      - Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Blinded Baseline Characteristics Align with Intended Study Population - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $258 million as of March 31, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmona

      5/15/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Financials

    Live finance-specific insights

    See more
    • Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

      - Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Blinded Baseline Characteristics Align with Intended Study Population - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $258 million as of March 31, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmona

      5/15/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

      Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, May 15, 2025, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: (800) 285-6670 International Dial-in Number: (713) 4

      5/12/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December

      3/13/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

      - Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.

      12/5/23 7:01:00 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

      Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise

      11/29/23 7:01:00 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

      Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),

      10/3/23 4:08:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care